Experience of a Vasopressin Receptor Antagonist, Tolvaptan, Under the Unique Indication in Japanese Heart Failure Patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-10

AUTHORS

K Kinugawa, T Imamura, I Komuro

ABSTRACT

Tolvaptan is a vasopressin type 2 receptor antagonist. Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function. Our review of this newly introduced drug is based on our experience in Japan. Clinical Pharmacology & Therapeutics (2013); 94 4, 449–451. doi:10.1038/clpt.2013.147 More... »

PAGES

449-451

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/clpt.2013.147

DOI

http://dx.doi.org/10.1038/clpt.2013.147

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033229856

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23872863


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antidiuretic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antidiuretic Hormone Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzazepines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osmolar Concentration", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Tokyo", 
          "id": "https://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "University of Tokyo Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine Tokyo Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kinugawa", 
        "givenName": "K", 
        "id": "sg:person.07421635332.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07421635332.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tokyo", 
          "id": "https://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "University of Tokyo Department of Cardiovascular Medicine, Graduate School of Medicine Tokyo Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imamura", 
        "givenName": "T", 
        "id": "sg:person.0632440723.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632440723.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tokyo", 
          "id": "https://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "University of Tokyo Department of Cardiovascular Medicine, Graduate School of Medicine Tokyo Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "I", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1517/14656566.2011.567267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009057930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1253/circj.cj-12-0971", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021891888"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-011-6304-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022847449", 
          "https://doi.org/10.1007/s10557-011-6304-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cardfail.2013.04.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042819043"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-10", 
    "datePublishedReg": "2013-10-01", 
    "description": "Tolvaptan is a vasopressin type 2 receptor antagonist. Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function. Our review of this newly introduced drug is based on our experience in Japan. Clinical Pharmacology & Therapeutics (2013); 94 4, 449\u2013451. doi:10.1038/clpt.2013.147", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/clpt.2013.147", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "94"
      }
    ], 
    "name": "Experience of a Vasopressin Receptor Antagonist, Tolvaptan, Under the Unique Indication in Japanese Heart Failure Patients", 
    "pagination": "449-451", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9e4d3a70509c70e6651c85b7dd11bdcacbf46b7ba030739d9c60590682c871a9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23872863"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0372741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/clpt.2013.147"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033229856"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/clpt.2013.147", 
      "https://app.dimensions.ai/details/publication/pub.1033229856"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000263.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1038/clpt.2013.147/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/clpt.2013.147'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/clpt.2013.147'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/clpt.2013.147'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/clpt.2013.147'


 

This table displays all metadata directly associated to this object as RDF triples.

125 TRIPLES      21 PREDICATES      40 URIs      28 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/clpt.2013.147 schema:about N4618bf3936de4791a9ce9759e609aef3
2 N68d4a38b75d640ee9d86bbf277b14211
3 N8126005eae6843daa586ddf695763f81
4 N8670e14014fd4666badcba4fcb26d8b3
5 N9e58bedf78b44f149da8a78c09725c43
6 Ndb29f71ae6294211a6cb671223f1626c
7 Nf310e42236b3431aa9bc026b107beb63
8 anzsrc-for:11
9 anzsrc-for:1102
10 schema:author N34fc847775e745579419a6711ee59e7b
11 schema:citation sg:pub.10.1007/s10557-011-6304-x
12 https://doi.org/10.1016/j.cardfail.2013.04.001
13 https://doi.org/10.1253/circj.cj-12-0971
14 https://doi.org/10.1517/14656566.2011.567267
15 schema:datePublished 2013-10
16 schema:datePublishedReg 2013-10-01
17 schema:description Tolvaptan is a vasopressin type 2 receptor antagonist. Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function. Our review of this newly introduced drug is based on our experience in Japan. Clinical Pharmacology & Therapeutics (2013); 94 4, 449–451. doi:10.1038/clpt.2013.147
18 schema:genre research_article
19 schema:inLanguage en
20 schema:isAccessibleForFree false
21 schema:isPartOf N3d86e275c7f840f9a76d209228ee054b
22 N7b7e494dff3c40bcb81d08d180a442e0
23 sg:journal.1017409
24 schema:name Experience of a Vasopressin Receptor Antagonist, Tolvaptan, Under the Unique Indication in Japanese Heart Failure Patients
25 schema:pagination 449-451
26 schema:productId N0f66f76bff8d41de9598465510d3f39e
27 N200e74b8cc634fa7a6480af59dc406f5
28 N8a9b6f38798445adad1d4f7ee3edd254
29 Nbe5402775f694a12b1f287bf2abc8cde
30 Ned7901ae13da4d8c89501af131e569e1
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033229856
32 https://doi.org/10.1038/clpt.2013.147
33 schema:sdDatePublished 2019-04-10T19:33
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N2a3d4e90c2b74dd3ae35ee16a1274149
36 schema:url http://onlinelibrary.wiley.com/doi/10.1038/clpt.2013.147/abstract
37 sgo:license sg:explorer/license/
38 sgo:sdDataset articles
39 rdf:type schema:ScholarlyArticle
40 N0f66f76bff8d41de9598465510d3f39e schema:name dimensions_id
41 schema:value pub.1033229856
42 rdf:type schema:PropertyValue
43 N200e74b8cc634fa7a6480af59dc406f5 schema:name doi
44 schema:value 10.1038/clpt.2013.147
45 rdf:type schema:PropertyValue
46 N2a3d4e90c2b74dd3ae35ee16a1274149 schema:name Springer Nature - SN SciGraph project
47 rdf:type schema:Organization
48 N34fc847775e745579419a6711ee59e7b rdf:first sg:person.07421635332.76
49 rdf:rest N5846deafc15f442594da65a4fe9a7202
50 N3d86e275c7f840f9a76d209228ee054b schema:issueNumber 4
51 rdf:type schema:PublicationIssue
52 N4618bf3936de4791a9ce9759e609aef3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Humans
54 rdf:type schema:DefinedTerm
55 N5846deafc15f442594da65a4fe9a7202 rdf:first sg:person.0632440723.57
56 rdf:rest Nbed20b5a8a474078b0256791a8fc3461
57 N68d4a38b75d640ee9d86bbf277b14211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Heart Failure
59 rdf:type schema:DefinedTerm
60 N7b7e494dff3c40bcb81d08d180a442e0 schema:volumeNumber 94
61 rdf:type schema:PublicationVolume
62 N8126005eae6843daa586ddf695763f81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Benzazepines
64 rdf:type schema:DefinedTerm
65 N8670e14014fd4666badcba4fcb26d8b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Antidiuretic Hormone Receptor Antagonists
67 rdf:type schema:DefinedTerm
68 N8a9b6f38798445adad1d4f7ee3edd254 schema:name nlm_unique_id
69 schema:value 0372741
70 rdf:type schema:PropertyValue
71 N9e58bedf78b44f149da8a78c09725c43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Osmolar Concentration
73 rdf:type schema:DefinedTerm
74 Nbe5402775f694a12b1f287bf2abc8cde schema:name pubmed_id
75 schema:value 23872863
76 rdf:type schema:PropertyValue
77 Nbed20b5a8a474078b0256791a8fc3461 rdf:first sg:person.01012024207.33
78 rdf:rest rdf:nil
79 Ndb29f71ae6294211a6cb671223f1626c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Antidiuretic Agents
81 rdf:type schema:DefinedTerm
82 Ned7901ae13da4d8c89501af131e569e1 schema:name readcube_id
83 schema:value 9e4d3a70509c70e6651c85b7dd11bdcacbf46b7ba030739d9c60590682c871a9
84 rdf:type schema:PropertyValue
85 Nf310e42236b3431aa9bc026b107beb63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Japan
87 rdf:type schema:DefinedTerm
88 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
89 schema:name Medical and Health Sciences
90 rdf:type schema:DefinedTerm
91 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
92 schema:name Cardiorespiratory Medicine and Haematology
93 rdf:type schema:DefinedTerm
94 sg:journal.1017409 schema:issn 0009-9236
95 1532-6535
96 schema:name Clinical Pharmacology & Therapeutics
97 rdf:type schema:Periodical
98 sg:person.01012024207.33 schema:affiliation https://www.grid.ac/institutes/grid.26999.3d
99 schema:familyName Komuro
100 schema:givenName I
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
102 rdf:type schema:Person
103 sg:person.0632440723.57 schema:affiliation https://www.grid.ac/institutes/grid.26999.3d
104 schema:familyName Imamura
105 schema:givenName T
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632440723.57
107 rdf:type schema:Person
108 sg:person.07421635332.76 schema:affiliation https://www.grid.ac/institutes/grid.26999.3d
109 schema:familyName Kinugawa
110 schema:givenName K
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07421635332.76
112 rdf:type schema:Person
113 sg:pub.10.1007/s10557-011-6304-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022847449
114 https://doi.org/10.1007/s10557-011-6304-x
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1016/j.cardfail.2013.04.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042819043
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1253/circj.cj-12-0971 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021891888
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1517/14656566.2011.567267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009057930
121 rdf:type schema:CreativeWork
122 https://www.grid.ac/institutes/grid.26999.3d schema:alternateName University of Tokyo
123 schema:name University of Tokyo Department of Cardiovascular Medicine, Graduate School of Medicine Tokyo Japan
124 University of Tokyo Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine Tokyo Japan
125 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...